Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00247078 · ClinicalTrials.gov registry record · Phase 2
The Efficacy and Safety of Aracmyn in Patients With Systemic Latrodectism
A Phase 2 study of Arachnidism and Latrodectism, sponsored by Instituto Bioclon S.A. de C.V..
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00247078 is a Phase 2 study of Arachnidism and Latrodectism that has completed, run by Instituto Bioclon S.A. de C.V.. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00247078, a Phase 2 study of Arachnidism and Latrodectism, has completed, sponsored by Instituto Bioclon S.A. de C.V..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the safety and effectiveness of an investigational antivenom and the current standard of care (pain management with opioid analgesics) for treating patients with a widow spider bite. The working hypotheses are as follows: 1. the investigational antivenom is more promptly effective at alleviating the pain associated with a widow spider bite than routine management with opioid pain medication 2. the investigational antivenom is as safe a treatment as opioid pain medication in treating patients with a widow spider bite.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL widow spider antivenom
Study Locations (1)
Colorado
- Denver Health and Hospital Authority - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2005-10 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00247078
The ClinicalTrials.gov registry entry for NCT00247078 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Instituto Bioclon S.A. de C.V., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Arachnidism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00247078 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT00247078 about?
NCT00247078 is a clinical study titled "The Efficacy and Safety of Aracmyn in Patients With Systemic Latrodectism". The purpose of this study is to compare the safety and effectiveness of an investigational antivenom and the current standard of care (pain management with opioid analgesics) for treating patients with a widow spider bite. The working hypotheses are as follows: 1. the investigational antivenom is m...
What is the current status of trial NCT00247078?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2005-10. Estimated completion is 2006-12.
What conditions does trial NCT00247078 study?
This clinical trial studies the following conditions: Arachnidism, Latrodectism.
What interventions are being tested in trial NCT00247078?
The interventions under investigation include: Placebo (BIOLOGICAL), widow spider antivenom (BIOLOGICAL).
Who is sponsoring clinical trial NCT00247078?
This trial is sponsored by Instituto Bioclon S.A. de C.V., which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00247078 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.